Finance May 7, 2026 1 min read
Novo Nordisk raised its full-year 2026 guidance after Q1 sales hit $15.2 billion (+32% constant currency), driven by the oral Wegovy pill which now commands 65% of new GLP-1 prescriptions in the United States.
Novo Nordisk raised its full-year 2026 guidance after Q1 sales hit $15.2 billion (+32% constant currency), driven by the oral Wegovy pill which now commands 65% of new GLP-1 prescriptions in the United States.